Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NANOSONICS LIMITED Board/Management Information 2017

Nov 1, 2017

65405_rns_2017-11-01_1c338c59-c220-401e-879d-0aa0c0ef1529.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [186 x 67] intentionally omitted <==

2 November 2017

Company Announcements Office Australian Securities Exchange

Notification of change of auditor

Nanosonics (ASX: NAN) advises that the Company has reviewed the role of its auditor. In accordance with good governance practice, and following a competitive tender, the Company has resolved to appoint Ernst & Young as its auditor.

As required by section 329(5) of the Corporations Act 2001 (Cth) (Corporations Act), the Australian Securities and Investments Commission has consented to the resignation of UHY Haines Norton as the auditor of Nanosonics, and UHY Haines Norton has provided written notice of its resignation to Nanosonics effective at the conclusion of the Company’s Annual General Meeting scheduled to be held on 3 November 2017.

The Corporations Act requires that shareholders approve the appointment of the new auditor. Accordingly, the appointment of Ernst & Young is subject to an ordinary resolution of shareholders at the Company’s Annual General Meeting. If the resolution is passed, the appointment of Ernst & Young will take effect from that date.

The Board of Directors would like to take this opportunity to thank UHY Haines Norton for their past assistance and services to the Company.

McGregor Grant Company Secretary

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company’s first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit www.nanosonics.com.au

Nanosonics Limited ABN 11 095 076 896 14 Mars Road, Lane Cove NSW 2066 Australia Tel: +61 2 8063 1600 Fax: +61 2 8063 1600 Email: [email protected] w: www.nanosonics.com.au